{"id":"curosurf-group1","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient oxygen desaturation"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Airway obstruction"},{"rate":null,"effect":"Pulmonary hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL1201622","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Curosurf is derived from porcine lung tissue and contains phospholipids and proteins that mimic endogenous pulmonary surfactant. It is administered intratracheally to restore surfactant function in neonates with respiratory distress syndrome, reducing alveolar collapse and improving lung compliance and oxygenation.","oneSentence":"Curosurf is a natural pulmonary surfactant that replaces deficient surfactant in the lungs to improve gas exchange and reduce surface tension in the alveoli.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:08.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory distress syndrome in premature infants"},{"name":"Meconium aspiration syndrome"}]},"trialDetails":[{"nctId":"NCT04715373","phase":"NA","title":"LISA in the Delivery Room for Extremely Preterm Infants","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-06-22","conditions":"Extreme Prematurity, Respiratory Distress Syndrome","enrollment":60},{"nctId":"NCT03655457","phase":"NA","title":"Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound","status":"UNKNOWN","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","startDate":"2018-03-21","conditions":"Lung Ultrasound Scores","enrollment":64},{"nctId":"NCT01709409","phase":"PHASE3","title":"A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-03","conditions":"Respiratory Distress Syndrome","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Curosurf-Group1","genericName":"Curosurf-Group1","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Curosurf is a natural pulmonary surfactant that replaces deficient surfactant in the lungs to improve gas exchange and reduce surface tension in the alveoli. Used for Respiratory distress syndrome in premature infants, Meconium aspiration syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}